A decade of HIV-1 drug resistance in the United States: Trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012

Antiviral Therapy

Volumn 19, Issue 4, 2014, Pages 435-441

  Paquet, Agnes C ^a   Solberg, Owen D ^a   Napolitano, Laura A ^a   Volpe, Joseph M ^a   Walworth, Charles ^a   Whitcomb, Jeannette M ^a   Petropoulos, Christos J ^a   Haddad, Mojgan ^a  

^a MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES; VIRAL TROPISM; VIRUS REPLICATION; YOUNG ADULT; DRUG EFFECTS; FACTUAL DATABASE; GENETICS; HISTORY; HIV INFECTIONS; PHYSIOLOGY;

ANTI-HIV AGENTS; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES; VIRAL TROPISM; VIRUS REPLICATION;

EID: 84929519296     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2748     Document Type: Article

References (17)

1. De Clercq E. Anti-HIV drugs. Verh K Acad Geneeskd Belg 2007; 69:81-104.
2. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-1199.
3. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
4. Hinkley T, Martins J, Chappey C, et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet 2011; 43:487-489.
5. Martins JZ, Chappey C, Haddad M, et al. Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments. Epidemics 2010; 2:85-91.
6. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.
7. Kosakovsky Pond SL, Posada D, Stawiski E, et al. An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLOS Comput Biol 2009; 5:e1000581.
8. Patel J, Livak B, Cole J, Vibhakar S, Max B, Smith KY. Efficacy and use of PI vs EFV in treatment naive HIV+ men and women. 52nd ICAAC. 9-12 September 2012, San Francisco, CA, USA. Abstract H-883.
9. Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1. Top Antivir Med 2013; 21:6-14.
10. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4:e4724.
11. Haddad M, Napolitano L, Frantzell A, et al. Combinations of HIV-1 reverse transcriptase mutations L100I+K103N/S and L100I+K103R+V179D reduce susceptibility to rilpivirine. 53rd ICAAC. 10-13 September 2013, Denver, CO, USA. Abstract H-677.
12. Buchacz K, Baker R, Ward DJ, et al. Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV outpatient study: 1999-2008. Aids Res Treat 2012; 2012:230290.
13. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339:961-965.
14. Maxmen A. Generic HIV drugs will widen US treatment net. Nature 2012; 488:267.
15. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
16. Wandeler G, Keiser O, Hirschel B, et al. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS ONE 2011; 6:e27903.
17. Ward CJ. Novel drugs and treatment strategies for HIV-1. Expert Rev Anti Infect Ther 2012; 10:1265-1267.